FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1976558206> ?p ?o ?g. }

• W1976558206 endingPage "1529" @default.
• W1976558206 startingPage "1524" @default.
• W1976558206 abstract "A multi-institution phase II study was undertaken by National Cancer Institute of Canada-Clinical Trials Group to evaluate the efficacy and toxicity of intravenous troxacitabine (Troxatyl; Shire Pharmaceuticals Plc, Laval, Quebec, Canada), in patients with renal cell carcinoma.Between June 1999 and March 2000, 35 patients (24 male) with a mean age of 60 years who had advanced and/or metastatic disease were treated with troxacitabine given as an intravenous infusion over 30 minutes at a dose of 10 mg/m2 intravenously, once every 3 weeks.Of the 33 of 35 patients evaluable for response, there were two confirmed partial responses, 21 patients had stable disease (median duration, 4.4 months), and 10 patients had progressive disease. Eight patients remained stable for more than 6 months, of whom six remain free of progression. The most common drug-related nonhematologic toxicities observed were skin rash (77.1%), hand-foot syndrome (68.6%), alopecia (51.4%), fatigue (51.4%), and nausea (57.1%). Out of a total of 145 cycles of treatment, 98 were given without steroid premedication, whereas 47 cycles were given with steroid premedication. Without premedication, skin rash occurred in 37% of cycles compared with 26% when steroids were given prophylactically.Troxacitabine given at a dose of 10 mg/m2 once every 3 weeks was well tolerated in patients with metastatic renal cell cancer, with common toxicities being a moderate to severe granulocytopenia and skin rash. Steroid premedication may reduce the frequency and severity of the skin rash. Our current study suggests that the nucleoside analog troxacitabine may have modest activity against renal cell carcinoma; however, larger studies are required to confirm this." @default.
• W1976558206 created "2016-06-24" @default.
• W1976558206 creator A5000204204 @default.
• W1976558206 creator A5003643368 @default.
• W1976558206 creator A5012084917 @default.
• W1976558206 creator A5013816209 @default.
• W1976558206 creator A5015979970 @default.
• W1976558206 creator A5019814247 @default.
• W1976558206 creator A5044291041 @default.
• W1976558206 creator A5045062801 @default.
• W1976558206 creator A5061327271 @default.
• W1976558206 creator A5063846121 @default.
• W1976558206 creator A5064229873 @default.
• W1976558206 creator A5067138875 @default.
• W1976558206 creator A5068552513 @default.
• W1976558206 creator A5076375756 @default.
• W1976558206 date "2003-04-15" @default.
• W1976558206 modified "2023-09-26" @default.
• W1976558206 title "Phase II Study of Troxacitabine (BCH-4556) in Patients With Advanced and/or Metastatic Renal Cell Carcinoma: A Trial of the National Cancer Institute of Canada-Clinical Trials Group" @default.
• W1976558206 cites W125728860 @default.
• W1976558206 cites W1500288385 @default.
• W1976558206 cites W1735360334 @default.
• W1976558206 cites W1939358691 @default.
• W1976558206 cites W1944650458 @default.
• W1976558206 cites W195499078 @default.
• W1976558206 cites W2003609490 @default.
• W1976558206 cites W2079270178 @default.
• W1976558206 cites W2143813821 @default.
• W1976558206 cites W2169884507 @default.
• W1976558206 cites W2414910088 @default.
• W1976558206 cites W24809853 @default.
• W1976558206 cites W4231601205 @default.
• W1976558206 cites W4234084352 @default.
• W1976558206 cites W4242609118 @default.
• W1976558206 cites W4247650177 @default.
• W1976558206 cites W88920869 @default.
• W1976558206 cites W99378550 @default.
• W1976558206 doi "https://doi.org/10.1200/jco.2003.03.057" @default.
• W1976558206 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12697876" @default.
• W1976558206 hasPublicationYear "2003" @default.
• W1976558206 type Work @default.
• W1976558206 sameAs 1976558206 @default.
• W1976558206 citedByCount "33" @default.
• W1976558206 countsByYear W19765582062013 @default.
• W1976558206 countsByYear W19765582062015 @default.
• W1976558206 countsByYear W19765582062016 @default.
• W1976558206 countsByYear W19765582062019 @default.
• W1976558206 countsByYear W19765582062021 @default.
• W1976558206 countsByYear W19765582062023 @default.
• W1976558206 crossrefType "journal-article" @default.
• W1976558206 hasAuthorship W1976558206A5000204204 @default.
• W1976558206 hasAuthorship W1976558206A5003643368 @default.
• W1976558206 hasAuthorship W1976558206A5012084917 @default.
• W1976558206 hasAuthorship W1976558206A5013816209 @default.
• W1976558206 hasAuthorship W1976558206A5015979970 @default.
• W1976558206 hasAuthorship W1976558206A5019814247 @default.
• W1976558206 hasAuthorship W1976558206A5044291041 @default.
• W1976558206 hasAuthorship W1976558206A5045062801 @default.
• W1976558206 hasAuthorship W1976558206A5061327271 @default.
• W1976558206 hasAuthorship W1976558206A5063846121 @default.
• W1976558206 hasAuthorship W1976558206A5064229873 @default.
• W1976558206 hasAuthorship W1976558206A5067138875 @default.
• W1976558206 hasAuthorship W1976558206A5068552513 @default.
• W1976558206 hasAuthorship W1976558206A5076375756 @default.
• W1976558206 hasConcept C121608353 @default.
• W1976558206 hasConcept C126322002 @default.
• W1976558206 hasConcept C141071460 @default.
• W1976558206 hasConcept C2777472916 @default.
• W1976558206 hasConcept C2778300832 @default.
• W1976558206 hasConcept C2778570526 @default.
• W1976558206 hasConcept C2780580376 @default.
• W1976558206 hasConcept C71924100 @default.
• W1976558206 hasConcept C90924648 @default.
• W1976558206 hasConceptScore W1976558206C121608353 @default.
• W1976558206 hasConceptScore W1976558206C126322002 @default.
• W1976558206 hasConceptScore W1976558206C141071460 @default.
• W1976558206 hasConceptScore W1976558206C2777472916 @default.
• W1976558206 hasConceptScore W1976558206C2778300832 @default.
• W1976558206 hasConceptScore W1976558206C2778570526 @default.
• W1976558206 hasConceptScore W1976558206C2780580376 @default.
• W1976558206 hasConceptScore W1976558206C71924100 @default.
• W1976558206 hasConceptScore W1976558206C90924648 @default.
• W1976558206 hasIssue "8" @default.
• W1976558206 hasLocation W19765582061 @default.
• W1976558206 hasLocation W19765582062 @default.
• W1976558206 hasOpenAccess W1976558206 @default.
• W1976558206 hasPrimaryLocation W19765582061 @default.
• W1976558206 hasRelatedWork W2002120878 @default.
• W1976558206 hasRelatedWork W2003938723 @default.
• W1976558206 hasRelatedWork W2047967234 @default.
• W1976558206 hasRelatedWork W2074843056 @default.
• W1976558206 hasRelatedWork W2118496982 @default.
• W1976558206 hasRelatedWork W2409218464 @default.
• W1976558206 hasRelatedWork W2439875401 @default.
• W1976558206 hasRelatedWork W2513113723 @default.
• W1976558206 hasRelatedWork W2884475036 @default.
• W1976558206 hasRelatedWork W2525756941 @default.
• W1976558206 hasVolume "21" @default.

• next